While genetic deletion of TRPV1 did not show a protective effect on CER-AP in mice (Romac et al., 2008), genetic deletion or pharmacological inhibition of TRPV1 has been consistently observed to reduce the severity of pancreatic inflammation, which was associated with the reduction of PAR2 activation, SP release, NK1R internalization, and 5-lipoxygenase expression as well as alleviated hyperalgesia in other experimental models of AP (Noble et al., 2006; Wick et al., 2006a; Nishimura et al., 2010; Vigna et al., 2011, 2014; Shahid et al., 2015). This evidence concerns the gene TFF2 and alkaline phosphatase measurement.